REX demonstrates exceptional financial health with a Piotroski F-Score of 8/9 and a nearly debt-free balance sheet (Debt/Equity 0.03). The current price of $49.97 is positioned between the defensive Graham Number ($32.29) and the growth-based Intrinsic Value ($73.75), suggesting reasonable valuation but limited immediate upside. While earnings growth is explosive, revenue remains stagnant, indicating that profitability is likely driven by tax credits and operational efficiency rather than organic growth. The outlook is tempered by a $58.2 million IRS audit and heavy reliance on federal 45Z and 45Q tax credits.